Reduced Content of α-Synuclein in Peripheral Blood Leukocytes of Patients with LRRK2-Associated Parkinson’s Disease

被引:0
|
作者
S. N. Pchelina
A. K. Emelyanov
A. F. Yakimovskii
D. W. Miller
I. G. Shabalina
A. S. Drozdova
A. L. Schwarzman
机构
[1] Russian Academy of Sciences,B. P. Konstantinov Petersburg Nuclear Physics Institute
[2] St. Petersburg State I. P. Pavlov Medical University,National Institute of Aging
[3] Ministry of Health Care and Social Development of the Russian Federation,undefined
[4] National Health Institute,undefined
关键词
Parkinson’s disease; α-synuclein; lymphocytes; leucine-rich kinase 2;
D O I
暂无
中图分类号
学科分类号
摘要
Measurement of α-synuclein level in the peripheral blood was proposed as a diagnostic test for Parkinson’s disease. However, the results of these studies remain contradictory, probably because the examined samples included patients with different etiology of Parkinson’s disease. To verify this assumption we studied the levels of α-synuclein in peripheral blood leukocytes of patients with Parkinson’s disease associated with mutations in the gene of leucine-rich kinase 2 (LRRK2). The mean α-synuclein level was signifi cantly lower in patients with LRRK2-associated Parkinson’s disease (N=8) than in patients with sporadic form of the disease (N=33; p<0.02) and in controls (N=18; p<0.05). On the other hand, we found no differences in the level of α-synuclein level between patients with sporadic form of the disease and controls. We hypothesize that the level of α-synuclein in the peripheral blood largely depends on the etiology of the disease and cannot be used as a universal diagnostic test for Parkinson’s disease.
引用
收藏
页码:679 / 681
页数:2
相关论文
共 50 条
  • [21] Motor Phenotype of LRRK2-Associated Parkinson's Disease: A Tunisian Longitudinal Study
    Nabli, Fatma
    Ben Sassi, Samia
    Amouri, Rim
    Duda, John E.
    Farrer, Matthew J.
    Hentati, Faycal
    MOVEMENT DISORDERS, 2015, 30 (02) : 253 - 258
  • [22] Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease
    Brockmann, K.
    Schulte, C.
    Schneiderhan-Marra, N.
    Apel, A.
    Pont-Sunyer, C.
    Vilas, D.
    Ruiz-Martinez, J.
    Langkamp, M.
    Corvol, J. -C.
    Cormier, F.
    Knorpp, T.
    Joos, T. O.
    Bernard, A.
    Gasser, T.
    Marras, C.
    Schule, B.
    Aasly, J. O.
    Foroud, T.
    Marti-Masso, J. F.
    Brice, A.
    Tolosa, E.
    Berg, D.
    Maetzler, W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (02) : 427 - E6
  • [23] Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
    Iakov N Rudenko
    Ruth Chia
    Mark R Cookson
    BMC Medicine, 10 (1)
  • [24] Immunomodulatory properties of hempseed oligopeptides in an LRRK2-associated Parkinson's disease animal model
    Torrecillas-Lopez, Maria
    Rivero-Pino, Fernando
    Trigo, Paula
    Toscano-Sanchez, Rocio
    Gonzalez-De la Rosa, Teresa
    Villanueva, Alvaro
    Millan-Linares, M. Carmen
    Montserrat-De la Paz, Sergio
    Claro-Cala, Carmen M.
    Food and Function, 2024, 15 (22): : 11115 - 11128
  • [25] Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
    Rudenko, Iakov N.
    Chia, Ruth
    Cookson, Mark R.
    BMC MEDICINE, 2012, 10
  • [26] Does Uncoupling Protein 2 Expression Qualify as Marker of Disease Status in LRRK2-Associated Parkinson's Disease?
    Gruenewald, Anne
    Arns, Bjoern
    Meier, Britta
    Brockmann, Kathrin
    Tadic, Vera
    Klein, Christine
    ANTIOXIDANTS & REDOX SIGNALING, 2014, 20 (13) : 1955 - 1960
  • [27] Comparing Rates of Motor Progression before and after DBS among Patients with Idiopathic and LRRK2-Associated Parkinson's Disease
    Viser, Aaron C.
    Leaver, Katherine
    Miravite, Joan
    Kopell, Brian H.
    Ortega, Robert
    Raymond, Deborah
    Bressman, Susan B.
    Saunders-Pullman, Rachel
    San Luciano, Marta
    ANNALS OF NEUROLOGY, 2020, 88 : S181 - S181
  • [28] Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease
    Weykopf, Beatrice
    Haupt, Simone
    Jungverdorben, Johannes
    Flitsch, Lea Jessica
    Hebisch, Matthias
    Liu, Guang-Hui
    Suzuki, Keiichiro
    Belmonte, Juan Carlos Izpisua
    Peitz, Michael
    Blaess, Sandra
    Till, Andreas
    Bruestle, Oliver
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (04) : 561 - 589
  • [29] Clinical traits of LRRK2-associated Parkinson's disease in Ireland:: A link between familial and idiopathic PD
    Gosal, D
    Ross, OA
    Wiley, J
    Irvine, GB
    Johnston, JA
    Toft, M
    Mata, IF
    Kachergus, J
    Hulihan, M
    Taylor, JP
    Lincoln, SJ
    Farrer, MJ
    Lynch, T
    Gibson, JM
    PARKINSONISM & RELATED DISORDERS, 2005, 11 (06) : 349 - 352
  • [30] The Therapeutic Potential of LRRK2 and α-Synuclein in Parkinson's Disease
    Sen, Saurabh
    West, Andrew B.
    ANTIOXIDANTS & REDOX SIGNALING, 2009, 11 (09) : 2167 - 2187